Breaking AI & Tech News Analyzed

Manchester United interim manager Michael Carrick strongly criticized the red card decision given to defender Lisandro Martínez during the team's 2-1 loss to Leeds United at Old Trafford. Martínez was sent off in the 56th minute for pulling the hair of Dominic Calvert-Lewin, a decision Carrick described as 'shocking' and one that may prompt an appeal.The red card could result in a three-match ban for Martínez, potentially sidelining him for United's upcoming fixtures against Chelsea, Brentford, and Liverpool. This comes at a critical time as Harry Maguire is also facing a possible suspension for his second yellow card in as many games.Carrick questioned the severity of the red card, stating, 'The arm [is] in the face of Lisandro and he is off balance and grappling. He goes to touch his shirt and gets a red card for it.' He emphasized that the incident did not constitute aggressive behavior, adding, 'It is not aggressive, there is no jolt, no tug.'The manager also expressed concern over another incident involving Noah Okafor's goal for Leeds, suggesting that Dominic Calvert-Lewin impeded Leny Yoro in the buildup. 'The goal, Leny Yoro gets a forearm smash in the back of the head. I don’t know how that doesn’t get overturned,' Carrick remarked.Leeds United's manager, Daniel Farke, reflected on the historic victory, stating, 'I feel tired, relieved, proud of the boys. The first league win here in over 40 years is amazing.'

Justin Rose secured a joint‑third place at the 2026 Masters, ending the tournament two shots behind defending champion Rory McIlroy. The result marked Rose’s third top‑six finish in his last eight major appearances. After a heartbreaking playoff loss to McIlroy at Augusta in 2025, Rose entered Sunday’s final round with the lead on the back‑nine but ultimately carded a final‑round 70 following a stumble at the famed Amen Corner. Reflecting on his performance, Rose said, "In the last two years I’ve really re‑kicked and re‑energised my career. I now have a lot of belief that there’s plenty of runway ahead." The 45‑year‑old, who claimed a PGA Tour victory in February, believes his recent form positions him to compete for future major titles. Rose emphasized that the majors are the events that drive his preparation: "These are the tournaments I focus on, the ones that make me put in that extra mile to show up and stay in these great arenas." His record at Augusta is notable, with eight top‑10 finishes and two runner‑up finishes, underscoring his affinity for the course. Rose cited veterans such as Freddie Couples and Bernhard Langer as inspirations, noting that the layout of Augusta rewards deep course knowledge and a personal playing style. Englishman Tyrrell Hatton also made headlines, posting a spectacular final‑round 66 that included six birdies and an eagle, propelling him to a joint‑third finish – his best performance in a major to date. Hatton explained his approach: "I try not to treat majors any differently – I go out every day, every round, every shot, and give it my best. I’m looking at ways to fine‑tune my preparation, perhaps more putting early in the week, to feel even more ready." Now in his tenth Masters, Hatton highlighted his steady improvement, citing recent top‑10 finishes at the U.S. Open and a rise from a tied‑fourteenth to a tied‑ninth in the last three years at Augusta.

Rachel Zegler has hailed the accessibility of Evita's free balcony scene, which became a landmark moment for London sightseers during the show's run last summer. The scene, which featured Zegler performing 'Don't Cry for Me Argentina' from the balcony of the London Palladium to crowds gathered on the street below, was a groundbreaking moment in theatre. At the Olivier awards on Sunday night, Zegler delivered the song again – this time on the stage of the Royal Albert Hall – and took home the award for best actress in a musical. Host Nick Mohammed noted that Zegler had become 'a new landmark for London sightseers' during Evita's run, allowing people who hadn't bought a ticket to watch the performance live for free on a giant screen. Zegler described Evita's director, Jamie Lloyd, as a 'genius' for staging the scene in such a way, giving 'a piece of theatre, just in the street' to young people who may not be able to afford West End ticket prices. 'It's so beautiful that Jamie Lloyd made such an accessible moment of theatre for people to walk by and witness something really, really cool,' she said. The actor, whose musical films include West Side Story and Snow White, praised Londoners for making her feel welcome and described those who had waited outside to watch the balcony scene as being 'so giving with their energy and love'. Zegler also acknowledged the difficulty of replicating the balcony scene, but she and Andrew Lloyd Webber have spoken of their hope that Evita will transfer to Broadway. Evita picked up two awards from five nominations at the Olivier awards, with choreographer Fabian Aloise also recognised for his work. The show was beaten to the prize for best musical revival by Into the Woods at the Bridge theatre.

While the two‑week pause in the US‑Israel campaign against Iran remains uncertain, one constant is clear: Donald Trump lacks a concrete plan, but Benjamin Netanyahu does. The war’s stated aim – to cripple Iran’s state capacity – is only a stepping stone toward a larger vision of a Greater Israel. For Israel’s right‑wing, the phrase often evokes a purely territorial ambition: enlarging the land Israel claims. History shows this expansionist drive has repeatedly displaced Palestinians, a process that has accelerated dramatically in recent years. Since the war began, Israel has flattened Gaza, killing tens of thousands and reducing the civilian‑inhabitable area to roughly 12 % of its pre‑war size. In the West Bank, a wave of settlement expansion and property destruction rivals the scale of the 1967 conflict. Beyond the occupied territories, Israel has seized parts of Syria and is forging a de‑facto occupation zone in southern Lebanon, with ministers from Religious Zionism, Jewish Power and Likud openly demanding Israeli sovereignty there. Finance minister Bezalel Smotrich even called for an expansion “to Damascus,” and Netanyahu has publicly expressed a deep personal connection to this territorial vision. However, Greater Israel is as much a geopolitical and strategic construct as a land‑grab. Netanyahu’s ambition extends beyond occupying borders; he seeks a regional dominion built on new alliances and hard‑power dependencies. After the October 7 attacks and the ensuing Gaza devastation, Israel’s prospects for Arab‑state normalization stalled. Faced with a choice between a conciliatory approach and a zero‑sum rejection of a Palestinian future, Netanyahu chose the latter, aiming to eliminate Iran as a regional counterweight – a move that inevitably required massive US military involvement. Former Israeli security analysts note that, from the perspective of Sunni Gulf states, a weakened Iran would elevate Israel to the role of “dominant regional power.” Achieving this, according to the article, also means softening the Gulf Cooperation Council (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, UAE) and making them dependent on Israel for security and energy routes. The spill‑over of Iranian drone and missile attacks on GCC infrastructure is portrayed not as an accident but as a calculated element of Israel’s strategy. When the US‑Israel coalition struck Iranian energy sites, Iran retaliated against the Gulf, disrupting global oil flows through the Strait of Hormuz. Netanyahu seized the moment to propose “alternative routes” – oil and gas pipelines that would bypass Hormuz and Bab‑al‑Mandab, ending at Israeli Mediterranean ports. In a meeting with Indian Prime Minister Narendra Modi, Netanyahu outlined a “hexagon of alliances” linking India, Arab nations, African states, Greece, Cyprus and other Asian partners, positioning Israel as the central hub. Recent IDF strategy papers echo this, suggesting Israel could achieve “operational control” far beyond its borders without permanent occupation, likening the Middle East to a “jungle” where Israel would become the “queen.” Netanyahu now describes Israel not merely as a “regional superpower” but, in some contexts, as a “global superpower.” He promises the hexagonal alliance will confront a “radical Shia axis” and an “emerging radical Sunni axis,” with Turkey singled out as the next strategic threat. Dismissal of the Greater Israel rhetoric as wartime hyperbole would be misleading. The article warns that a permanent war‑oriented mindset permeates Israel’s political elite, security establishment and media, posing a risk of overreach and regional blowback. Containing this expansive vision may become one of the most pressing post‑war challenges for the Middle East.

Recent CDC data reveal a dramatic 1,200% increase in kratom‑related poisonings across the United States over the last ten years, with the most pronounced surge recorded in 2025. Researchers link this rise to the growing presence of 7‑hydroxymitragynine (7‑OH), a synthetically produced compound that mimics kratom’s effects but carries opioid‑like risks. Walter Prozialeck, pharmacology professor at Midwestern University, said the trend was expected, noting that the synthetic alkaloid has entered the market through energy drinks and other products since 2024. Christopher McCurdy of the University of Florida warned that marketing 7‑OH as “enhanced kratom” blurs the line for consumers, turning poison‑control calls into a conflated metric for both natural and synthetic products. By contrast, natural kratom (Mitragyna speciosa)—a Southeast Asian plant used for centuries as a pain reliever—has demonstrated a relatively favorable safety profile in animal and human studies. A 2018 statement from then‑HHS Secretary Brett Giroir rejected the DEA’s push to schedule kratom as a Schedule I substance, citing insufficient evidence of harm. Despite the scientific distinction, several states have moved to implement or propose blanket bans on all kratom products, prompting concern from clinicians and patient advocates. A recent user survey indicated that about 50% of respondents rely on kratom for chronic pain, while roughly 40% use it during addiction recovery. Personal testimonies underscore the plant’s therapeutic role. Jeff Maslan, a 68‑year‑old Californian with severe osteoarthritis, credits kratom with easing opioid withdrawal after multiple surgeries. Similarly, “Steven,” a disabled California resident, describes how kratom eliminated unbearable oxycodone withdrawal symptoms without producing the euphoric “warm fuzzy” feeling typical of opioids. Researchers emphasize that 7‑OH carries genuine opioid hazards, including addiction, severe withdrawal, and respiratory depression that can lead to fatal overdose. In animal models, 7‑OH demonstrated the same respiratory‑depression risk as classic opioids, whereas kratom’s primary alkaloid did not. Prozialeck and colleagues explain that kratom’s pharmacology is more nuanced: it partially activates opioid receptors while also engaging adrenergic and serotonin pathways, resembling a hybrid of a weak opioid and an SNRI‑type antidepressant. This multimodal action likely accounts for its lower euphoric potential and the reported boost in energy among users. Nevertheless, experts caution that kratom is not without risk. Fatal poisonings often involve co‑ingestion of potent opioids such as fentanyl, suggesting that some users may cycle between kratom and stronger substances, raising overdose danger due to reduced opioid tolerance. Additionally, heavy‑metal contamination has been detected in certain kratom batches, though the source—soil, processing, or storage—remains unclear. Given these complexities, the consensus among scholars like Austin Zamarripa (Johns Hopkins) is that natural kratom should remain accessible, while concentrated 7‑OH products merit stricter regulation. “These products may offer meaningful benefits to some individuals, and those benefits could be lost if access is restricted too broadly,” Zamarripa said, urging a differentiated policy approach. As the debate unfolds, patients like Steven worry that a sweeping ban would ignore the nuanced safety profile of the plant. “There’s corn on the cob, there’s high‑fructose corn syrup, there’s whiskey— all derived from corn but fundamentally different,” he remarked, highlighting the need for targeted, evidence‑based regulation rather than a one‑size‑fits‑all prohibition.

Scientists at London's Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have announced a new AI-driven approach to identify how patients with advanced bowel cancer will respond to bevacizumab, a drug recently introduced by the NHS. The method uses PhenMap, an AI tool that integrates complex data on the genetic makeup of tumors, allowing researchers to track patterns of how different patients react to the drug. This development aims to spare potentially thousands of patients from being given drugs that would be ineffective in fighting their cancers. In the UK alone, nearly 10,000 cases of advanced bowel cancer are identified every year, with young adults seeing a particular rise in diagnoses. Bowel cancer has the second-highest mortality rate of any cancer, behind only lung cancer. While survival rates can be as high as 98% when caught early, the five-year survival rate for advanced bowel cancer can be as low as 10%. The study tracked 117 European bowel cancer patients who had been treated with chemotherapy and bevacizumab. Researchers identified a group of patients who all had the same gene mutation and were at a high risk of having negative reactions. The scientists behind the tests now hope to expand the number of patient samples and see if the results can be used in treatments for other types of cancer. Anguraj Sadanandam, a professor in stratification and precision medicine at the ICR, said: “Once bowel cancer spreads to other parts of the body, there are very few treatment options available for patients. It is therefore positive that patients can now access the targeted drug bevacizumab on the NHS. However, we know that the majority of patients won’t benefit from the drug, meaning thousands of people in England could be facing unpleasant side effects unnecessarily.” Sadanandam added that while the findings were encouraging, the tool would need to be tested on a larger cohort to be validated. “In future, I hope this approach will lead to a test that can be used by clinicians, to ensure patients receive personalised care that has the highest chance of working against their cancer.”

Australian sprint prodigy Gout Gout stunned the athletics community on Sunday at the national championships in Sydney, clocking a legal 19.67 seconds over 200 m. The performance not only smashed his own previous national record of 20.02 seconds but also made him the first Australian to dip below the coveted 20‑second barrier. Gout’s coach and mentor, Di Sheppard, summed up the achievement with a wry grin: “How long’s a piece of string?” – a nod to the seemingly limitless potential the teenager now displays. The run placed Gout ahead of his compatriot Aidan Murphy, who finished a close second, and sparked immediate comparisons with Jamaican legend Usain Bolt. While Bolt’s all‑time best stands at 19.19 seconds (set in 2009), Gout’s 19.67 at the age of 18 already eclipses the Jamaican great’s performance at the same age, according to his camp. Only one other under‑20 athlete has ever posted a faster time – Erriyon Knighton – whose 2022 effort remains unratified after a subsequent ban. James Templeton, the 18‑year‑old’s manager, said the result was “thrilling but not shocking”, recalling that Gout ran 19.84 seconds the previous year with a marginal wind assistance, a time the team always considered his realistic benchmark. Gout himself has been fixated on breaking the sub‑20 mark ever since an illegal run earlier in his career. “I wrote down 19.75 and kept telling myself I’d hit it,” he explained. “Then I hit 19.67 – gotta love it.” Despite the historic run, the teenager shows no intention of slowing down. “I’ve just turned 18, so I definitely think I can go faster,” he said. “It’s about building consistency and there’s no pressure – I’m the only one out there.” Looking ahead, Gout will compete in the under‑20 junior championships this week, opting to skip the 200 m in Queensland and focus on the 100 m. He will then travel overseas for a high‑profile showdown with Olympic champion Noah Lyles over 150 m at the Golden Spike meet in Ostrava, scheduled for June. Should Gout continue his upward trajectory, the athletics world may soon witness a new challenger to Bolt’s long‑standing age‑group record, reshaping expectations for the next generation of sprint talent.

Scotland staged a late comeback to beat Wales 27‑22 in what was hailed as the best match of the opening weekend of the Women’s Six Nations, played at Cardiff’s Principality Stadium. The game attracted 10,569 spectators, the highest ever attendance for a Wales‑Scotland women’s clash on Welsh soil, though the venue’s 74,500‑seat capacity meant the atmosphere fell short of the stadium’s potential. Wales, led by head coach Sean Lynn, fought back from a 24‑12 halftime hole, narrowing the gap to five points in the closing minutes. Despite a valiant effort from their own try line, a mishandled line‑out in the dying seconds denied them a first Six Nations win since their 22‑20 victory over Italy in 2024. Scotland’s triumph was especially significant for new head coach Sione Fukofuka, who secured his inaugural win since taking the reins in December. Fly‑half Helen Nelson, named player of the match, praised the team’s defensive resilience and the blend of experienced and emerging talent. The match formed part of the Welsh Rugby Union’s strategy to showcase the women’s game in the national stadium, with plans to host at least one fixture there each season, hoping larger crowds will follow. Across the tournament, England set a new attendance benchmark with 77,120 fans at Twickenham for their 33‑12 win over Ireland, while upcoming fixtures promise further milestones: Scotland will play a standalone game at Murrayfield before heading to Dublin, and France, after a strong second‑half display against Italy, now sit atop the table on points difference. Looking ahead, Wales will face France at Cardiff Arms Park, where two of the three stands are already sold out, as the team aims to build on the “fight and character” displayed in Saturday’s encounter.

At the break of day in Keswick, the air still carries a chill despite it being April. From a drystone wall on St John’s Vale, I watched the sky race past Helvellyn, while bright daffodils bowed on a nearby farm as if shivering in the breeze. The surrounding trees stood still, and a shaft of sunlight ignited the bracken below the crags, turning it a vivid colour that starkly contrasted with the dead grass and dark scree. This scene illustrates a place where change has settled gently, with farms preserving their protective belts of trees that nestle comfortably against the fell’s edge.The low fields echoed with the call of curlews, and although some farmers elsewhere lament a lack of moisture, the land here was saturated; the river ran brown with flood‑water and the becks churned white. Many ewes were gathered for lambing, yet one independent ewe chose to give birth alone on a small green shelf in a ghyll above a stream. The newborn lamb was still damp and trembling when a farmhand arrived in his tractor, loading the pair onto a hay‑lined trailer to bring them back to the safety of the farm, fearing the lamb might tumble into the beck as its mother went to drink.